

KFIN/GXP/SEP/2021
October 5, 2021

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli
Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended September 30, 2021.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2021.

Description of Complaint	Opening Balance as on 01.07.2021	Received during the Period 01.07.2021 to 30.09.2021	Attended/Resolved during the Period 01.07.2021 to 30.09.2021	Pending as on 30.09.2021
Non-receipt of Dividend	NIL	20	20	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of share certificates	NIL	02	02	NIL
SEBI	NIL	NIL	NIL	NIL
Stock Exchange	NIL	02	02	NIL
Total	NIL	24	24	NIL

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Private Limited



Rajitha Cholleti
Asst. General Manager